- Home
- SRZN vs ICCC Comparison
SRZN vs ICCC Comparison
Compare SRZN & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- ICCC
- Stock Information
- Founded
- SRZN 2015
- ICCC 1982
- Country
- SRZN United States
- ICCC United States
- Employees
- SRZN N/A
- ICCC N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- ICCC Health Care
- Exchange
- SRZN Nasdaq
- ICCC Nasdaq
- Market Cap
- SRZN 37.7M
- ICCC 39.2M
- IPO Year
- SRZN N/A
- ICCC 1987
- Fundamental
- Price
- SRZN $11.43
- ICCC $4.96
- Analyst Decision
- SRZN Strong Buy
- ICCC
- Analyst Count
- SRZN 2
- ICCC 0
- Target Price
- SRZN $38.50
- ICCC N/A
- AVG Volume (30 Days)
- SRZN 12.4K
- ICCC 13.6K
- Earning Date
- SRZN 03-31-2025
- ICCC 05-13-2025
- Dividend Yield
- SRZN N/A
- ICCC N/A
- EPS Growth
- SRZN N/A
- ICCC N/A
- EPS
- SRZN N/A
- ICCC N/A
- Revenue
- SRZN $10,655,000.00
- ICCC $26,493,000.00
- Revenue This Year
- SRZN N/A
- ICCC N/A
- Revenue Next Year
- SRZN N/A
- ICCC N/A
- P/E Ratio
- SRZN N/A
- ICCC N/A
- Revenue Growth
- SRZN N/A
- ICCC 51.63
- 52 Week Low
- SRZN $6.00
- ICCC $3.34
- 52 Week High
- SRZN $18.17
- ICCC $5.82
- Technical
- Relative Strength Index (RSI)
- SRZN 53.51
- ICCC 49.78
- Support Level
- SRZN $10.34
- ICCC $4.56
- Resistance Level
- SRZN $14.00
- ICCC $5.05
- Average True Range (ATR)
- SRZN 0.95
- ICCC 0.27
- MACD
- SRZN 0.00
- ICCC 0.01
- Stochastic Oscillator
- SRZN 47.36
- ICCC 55.74
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.